[Targeted HCC therapies: the door has been opened!]

[Article in French]

Free article

Editorial

[Article in French]

O Rosmorduc et al. Gastroenterol Clin Biol. 2008 Jan.

Free article

. 2008 Jan;32(1 Pt. 1):1-2.

doi: 10.1016/j.gcb.2007.12.001. Epub 2008 Mar 4.

No abstract available

Similar articles

Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX. Zhu AX. Expert Rev Anticancer Ther. 2008 Apr;8(4):499-505. doi: 10.1586/14737140.8.4.499. Expert Rev Anticancer Ther. 2008. PMID: 18402516 No abstract available.
[An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A, Graeven U. Lang A, et al. Zentralbl Chir. 2009 Jun;134(3):189-92. doi: 10.1055/s-0029-1224838. Epub 2009 Jun 18. Zentralbl Chir. 2009. PMID: 19544236 German. No abstract available.
Targeted therapies for hepatocellular carcinoma.
Skelton MR, O'Neil B. Skelton MR, et al. Clin Adv Hematol Oncol. 2008 Mar;6(3):209-18. Clin Adv Hematol Oncol. 2008. PMID: 18391920 Review.
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V, Barbare JC, Rosmorduc O; Groupe de travail carcinome hépatocellulaire Prodige-Afef. Boige V, et al. Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4. Gastroenterol Clin Biol. 2008. PMID: 18341970 French. No abstract available.
Novel molecular therapies in hepatocellular carcinoma.
Faivre S, Bouattour M, Raymond E. Faivre S, et al. Liver Int. 2011 Jan;31 Suppl 1:151-60. doi: 10.1111/j.1478-3231.2010.02395.x. Liver Int. 2011. PMID: 21205154 Review.